P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Roxana Mehran, Shamir R. Mehta et al.|BMJ|2021Cited by 254
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Luca Bergamaschi et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Luca Bergamaschi et al.|Pharmacological Research|2022Cited by 146
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Marco Valgimigli, Roxana Mehran et al.|Journal of the American College of Cardiology|2023Cited by 119
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trialsMarco Valgimigli, Myeong‐Ki Hong, Sung‐Jin Hong et al.|The Lancet|2024Cited by 93